A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib (NCT06876649)
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
🩺 Plain-English Summary (8th-Grade Level)
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
Who can join: Review the eligibility criteria below.
Location: Cancer Specialists, LLC — Jacksonville, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (38 Sites)
Showing the first 25 of 38 sites.
- Cancer Specialists, LLC — Jacksonville, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
- Florida Cancer Specialists — Sarasota, Florida
- The Emory Clinic — Atlanta, Georgia
- Northwestern University — Chicago, Illinois
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic- Minnesota — Rochester, Minnesota
- University Of Nebraska Medical Center — Omaha, Nebraska
- Cayuga Cancer Center — Ithaca, New York
- Northwell Health — Lake Success, New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York — New York, New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York — New York, New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York — New York, New York
- Duke University Medical Center — Durham, North Carolina
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- University of Pennsylvania Hospital — Philadelphia, Pennsylvania
- Tennessee Oncology — Nashville, Tennessee
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Swedish Cancer Institute — Seattle, Washington
- Medical College of Wisconsin — Milwaukee, Wisconsin
- Flinders Medical Centre — Adelaide,
- Peter MacCallum Cancer Centre — Melbourne,
- Linear Clinical Research — Victoria,
- CHU de Nantes - Hotel Dieu — Nantes,
- IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi — Bologna,
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Lymphocytic Leukemia
- Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia — Houston, Texas
- Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia — Rochester, Minnesota
- A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) — Anchorage, Alaska
- Economic Analysis of Alliance A041202 CLL Study — Calgary, Alberta
- A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL — Chandler, Arizona
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) — Phoenix, Arizona
Explore by condition: All Chronic Lymphocytic Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.